Antiplatelet Therapy in Acute Coronary Syndrome | Zendy

Kerry Layne | Zendy; Albert Ferro | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antiplatelet Therapy in Acute Coronary Syndrome

Author(s) -

Kerry Layne,

Albert Ferro

Publication year - 2017

Publication title -

european cardiology review

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 0.864

H-Index - 12

eISSN - 1758-3764

pISSN - 1758-3756

DOI - 10.15420/ecr.2016:34:2

Subject(s) - medicine , acute coronary syndrome , antithrombotic , aspirin , unstable angina , myocardial infarction , cardiology , antiplatelet drug , intensive care medicine , platelet aggregation inhibitor , clopidogrel

Antiplatelet agents have for decades been used to improve outcomes in patients with acute coronary syndromes and have become increasingly valued, not only for their antithrombotic properties but also for their anti-inflammatory effects. The drug class continues to evolve as novel agents with increasingly efficacious antiplatelet actions are identified. This review will discuss antiplatelet agents, including aspirin, the P2Y 12 receptor antagonists and the glycoprotein IIb/IIIa inhibitors, that are currently used to treat patients with unstable angina and myocardial infarction, focusing on their pharmacological properties and the clinical evidence supporting their use.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research